Saridegib (IPI-926) (Synonyms: IPI-926; Patidegib) |
| Katalog-Nr.GC32978 |
Saridegib (IPI-926) ist ein potenter und spezifischer Inhibitor von Smoothened (Smo), einem SchlÜsseltransmembran-Signalprotein im Hedgehog (Hh)-Signalweg.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1037210-93-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model[1].
[1]. Ko AH, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *